Building our economic recovery around life sciences


In just over a month, Scottish voters will go to the polls to elect the next Scottish govern- ment and regardless of who is returned to St Andrews House they will find an in-tray packed with problems to solve. Covid-19 has dominated the

last 12 months, with regional lockdowns and rolling restric- tions taking a huge toll on the nation’s collective health and wealth. Getting Scotland back to

work, children back to school, and the NHS back to normal will require clear thinking and a joined-up approach from government. During the crisis, the

pharmaceutical industry has worked hard to support the NHS. Our members have prioritised the supply of critical medicines whilst devoting time and resources to discovering the latest Covid-19 vaccines and treatments. Te ability to develop and deploy cutting- edge vaccines so efficiently will go down as one of our greatest scientific achievements. Unfortunately, the fight isn’t

over, and the next stage of the pandemic will turn to how we rebuild our economy and healthcare system. Recent research revealed that

the pharmaceutical industry supports over 15,000 jobs in Scotland. Tis success isn’t built on low-paid employment, but instead, on high-quality jobs that extend to every corner of the country. Most of these jobs can be found in tradition- ally deprived communities and rural areas, with the industry contributing positively to the Scottish Government’s inclu- sive growth agenda. However, despite this suc-

cess, we can’t rest on our laurels. Countries across the globe are clamouring for phar- maceutical investment and if Scotland wants to stay ahead of the pack, we must be bold and ambitious. Ahead of the election in May,

ABPI Scotland believes that the next government should build our economic recovery around life sciences and empower the sector to grow through in- creased collaboration and the speedy return of clinical trials. Beyond the economy, it is

vital that the NHS is able to tackle the current treatment backlog and we believe that the faster adoption of in- novative medicine can help improve care and reduce strain on clinicians.

And finally, linking all of this together, is data. During the pandemic, data and digital solutions have provided vital lessons for the NHS. In helping facilitate research, plan treat- ments, and beam consultations into patient homes, digital so- lutions have been at the heart of NHS thinking. For industry, improved use of large data sets will transform research and development and patient ac- cess to medicine and must be a priority going forward. A thriving life sciences sec-

tor has the potential to cure all ills and these actions, when taken together, provide the blueprint for Scotland to trans- form its health and wealth. We hope the next government agrees. l

Alison Culpan is the Director of ABPI Scotland

Tech to monitor Covid-19 remotely

CARP platform in trials with Glasgow patients

A new digital solution that predicts respiratory failure in Covid-19 patients who have left critical care has secured funding. Te Covid-19 Advanced Re-

spiratory Physiological (CARP) platform is being trialled in respiratory failure patients across Glasgow after securing funding from the Scottish Government’s Chief Scientist Office. Te technology is being devel-

oped in partnership between by digital transformation consul- tancy Storm ID, NHS Greater Glasgow and Clyde and Altair Medical and will help clinicians monitor patients continuously once they have left direct care. A key challenge faced by hospi-

tals in the coronavirus pandemic is the need to monitor an unprec- edented number of patients. Tis is made more challenging by the fact that patients with Covid-19 are at risk of sudden deteriora- tion. Respiratory rate and breath- ing events are a key predictor of deterioration but, until now, hospitals have been unable to monitor patient respiratory health remotely or at scale. CARP will use Altair Medical’s

wearable sensor and respiratory algorithms in conjunction with a clinical dashboard, made possible by Storm ID’s Lenus Health Plat- form, to gather patient respiratory data.

Te Lenus Health Platform

allows the de-identified trial data to be aggregated for machine- learning analyses, to develop risk predictive models in-silico (with computer simulation). If subse- quent effectiveness trials proved the utility of these models, CARP would provide the infrastructure for clinicians to identify and tri- age at-risk patients in real-time. Te project is funded by the

University of Glasgow as part of the Chief Scientist Office Rapid Research in Covid-19 programme. “Our Lenus Health Platform

supports remote patient moni- toring and so it was only natural for us to look at how this could be made available to Covid-19 patients. Te CARP solution will provide a basis for exploring how the NHS can use this innovative sensor to proactively monitor patients,” said Paul McGinness, director at Storm ID. “CARP will provide us with

critical, real-time capability to identify and triage Covid-19 patients at risk of deterioration. Tis will greatly assist clinicians as patient numbers increase,” said Dr Chris Carlin, consultant physician at NHS Greater Glasgow and Clyde. Dr Bruce Henderson, chief exec-

utive of Altair Medical, said: “Te CARP trial has allowed unique in- sights into the effects of Covid-19 and the data analysis methods developed will enhance the use of Altair Medical’s technology in a range of respiratory conditions. Tis would not have been possible without the Lenus Health Platform – it provides a pivotal link in safely and securely maximising the real- world utility of biosensor data.”l


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44